EUCTR2006-002977-33-SI进行中（未招募）不适用
Safety and efficacy of intravitreal injections of ranibizumab/Lucentis in combination with verteporfin photodynamic therapy (PDT) in patients with choroidal neovascularisation (CNV) secondary to age related macular degeneration
niversity Eye Hospital0 个研究点目标入组 10 人开始时间: 2006年8月21日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients who at baseline
- •have a BCVA letter score in the study eye between 73-24 (approximately 20/40 to 20/320) using an ETDRS chart measured at 4 meters or Snellen equivalent
- •have a CNV lesion of any type in the study eye with the following characteristics as determined by fluorescein angiography:
- •oEvidence that CNV extends under the geometric center of the foveal avascular zone.
- •oThe area of the CNV must occupy at least 50% of the total lesion.
- •oThe lesion must be =5400 microns in greatest linear dimension (GLD)
- •for occult with no classic CNV, the lesion must have presumed recent disease progression as assessed by the Investigator and defined as having at least one of the following criteria:
- •oBlood associated with the lesion at baseline
- •oLoss of VA in the previous 3 months defined as either
- •o=5 letters (ETDRS equivalent) as determined by protocol refraction and protocol measurement
- •o2 or more lines using a Snellen or equivalent chart by standard examination
- •o=10% increase in the GLD as assessed by fluorescein angiography in the previous 3 months
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients who have a BCVA of < 33 letters (approximately 20/200) in both eyes
- •Prior treatment in the study eye with verteporfin, external-beam radiation therapy, vitrectomy, submacular surgery, other surgical intervention for AMD, or transpupillary thermotherapy
- •Previous or current intravitreal drug delivery (e.g., intravitreal corticosteroid injection or device implantation) in the study eye
- •Focal laser photocoagulation (juxta-, extra- or subfoveal ) in the study eye
- •Concomitant use of chronic NSAIDs or steroids (by any route) for the duration of study participation (chronic use is defined as multiple doses taken daily for three or more consecutive days at any time during the study). Note that ASA (aspirin) taken as low dose” up to 100 mg daily (qd) for prophylaxis of myocardial infarction (MI) and/or stroke is permitted during study
- •Current use or likely need for systemic medications known to be toxic to the lens, retina or optic nerve, including Deferoxamine, Chloroquine/ hydroxychloroquine (Plaquenil), Tamoxifen, Phenothiazines and Ethambutol is excluded
- •History of glaucoma filtration surgery, corneal transplant surgery or extracapsular extraction of cataract with phacoemulsification within six months preceding Day One, or a history of post-operative complications within the last 12 months preceding Day One in the study eye (uveitis, cyclitis etc.)
- •History of uncontrolled glaucoma in the study eye (defined as intraocular pressure = 25 mmHg despite treatment with topical anti-glaucomatous medication).
- •Aphakia or absence of the posterior capsule in the study eye
- •Previous violation of the posterior capsule in the study eye is also excluded unless it occurred as a result of YAG posterior capsulotomy in association with prior, posterior chamber intraocular lens implantation
- •Spherical equivalent of the refractive error in the study eye demonstrating more than –8 diopters of myopia
- •Presence of a retinal pigment epithelial tear involving the macula in the study eye
- •Angioid streaks or precursors of CNV in either eye due to other causes, such as ocular histoplasmosis, trauma, or pathologic myopia
- •Active intraocular inflammation (grade trace or above) in the study eye
- •Any active infection involving an eyeball adnexa
- •Vitreous hemorrhage or history of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the study eye
研究者
相似试验
进行中（未招募）
不适用
Evaluation of safety and efficacy of intravitreal bevacizumab for macular edema, retinal or choroidal neovascularization or neovascular glaucoma - NDMacular oedemaMedDRA version: 6.1Level: HLGTClassification code 10047060EUCTR2006-002351-33-ITAZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA
进行中（未招募）
不适用
Evaluation of efficacy and safety of Intravitreal bevacizumab versus intravitreal bevacizumab combined with juxtascleral anecortave acetate for the treatment exudative age-related macular degeneration - IVB JSAEUCTR2006-003170-99-ITIVERSITA DEGLI STUDI DI UDINE
招募中
不适用
Clinical evaluation for the effects of intraocular tissue plasminogen activator administration in various eye diseasesVarious eye diseasesJPRN-UMIN000015726Department of Ophthalmology, Shimane University Faculty of Medicine, Izumo, Japan50
未知
1 期
To evaluate safety and efficacy of intravitreal Bevaxizumab injection for intraocular neovasculalizatioARMD,BRVO,CRVO,DR,CNVJPRN-UMIN000000647Department of Ophtalmology of Keio University Hospital10
已完成
2 期
Intravitreal injection of methotrexate in persistent diabetic macular edemaResistant macular edema in diabetic patients.Distrubtion of retinal layers due to edemaIRCT201610098983N2Guilan University of Medical Sciences,Vice chancellor for research42